Literature DB >> 8607812

A comparative analysis of the photosensitized inhibition of growth-factor regulated protein kinases by hypericin-derivatives.

P Agostinis1, A Donella-Deana, J Cuveele, A Vandenbogaerde, S Sarno, W Merlevede, P de Witte.   

Abstract

The photodynamic inhibitory effect of hypericin and a number of hypericin-derivatives were investigated in vitro using numerous growth-factor regulated protein kinases including receptor-bound (Insulin-R, EGF-R) and non-receptor (Lyn, c-Fgr, CSK, Syk) protein tyrosine kinases as well as Ser/Thr (PK-C, protein kinase CK-2, CK-1) protein kinases. Modification of the hypericin structure altered significantly the specificity of the protein kinase inhibition. In particular, methylation or attachment of long lipophilic chains to both methyl groups of the hypericin molecule strongly enhanced the specificity toward PK-C.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8607812     DOI: 10.1006/bbrc.1996.0451

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

1.  St. John's Wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats.

Authors:  Zeping Hu; Xiaoxia Yang; Paul Chi-Liu Ho; Eli Chan; Sui Yung Chan; Congjian Xu; Xiaotian Li; Yi-Zhun Zhu; Wei Duan; Xiao Chen; Min Huang; Hongyuan Yang; Shufeng Zhou
Journal:  Pharm Res       Date:  2005-06-08       Impact factor: 4.200

2.  Photodynamic therapy activated signaling from epidermal growth factor receptor and STAT3: Targeting survival pathways to increase PDT efficacy in ovarian and lung cancer.

Authors:  Christine Edmonds; Sarah Hagan; Shannon M Gallagher-Colombo; Theresa M Busch; Keith A Cengel
Journal:  Cancer Biol Ther       Date:  2012-09-17       Impact factor: 4.742

3.  A photodynamic pathway to apoptosis and necrosis induced by dimethyl tetrahydroxyhelianthrone and hypericin in leukaemic cells: possible relevance to photodynamic therapy.

Authors:  G Lavie; C Kaplinsky; A Toren; I Aizman; D Meruelo; Y Mazur; M Mandel
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

4.  Hypericin, a potential new BH3 mimetic.

Authors:  Anastasia Doroshenko; Silvia Tomkova; Tibor Kozar; Katarina Stroffekova
Journal:  Front Pharmacol       Date:  2022-10-04       Impact factor: 5.988

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.